8th meeting for Keytruda’s 3+ yrs pending reimb. to be held
By Eo, Yun-Ho | translator Alice Kang
21.05.20 16:33:06
가나다라
0
Meeting to be held on the 26th… MSD Korea proposed an alternative equivalent to the burden of the initial administration cost
A virtual failure if the final cost-sharing proposal is rejected…eyes are on whether the committee accepts the proposal
According to industry sources, MSD Korea’s application to expand the reimbursement of ‘Keytruda (pembrolizumab)’ to cover first-line treatment of non-small cell lung cancer (NSCLC) is expected to be put on the agenda for deliberation by the Cancer Drug Review Committee on the 26th. In March, MSD Korea had once again revised and submitted a final cost-sharing proposal to the Health Insurance Review & Assessment Service (HIRA).
The reimbursement expansion for Keytruda had been discussed since September 2017, and over 3 years had already passed with no result. The biggest bar
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)